Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: A three-year surveillance from 2004 to 2006

Virologica Sinica

Volumn 26, Issue 6, 2011, Pages 386-392

  Gong, Jian ^a,b   Wang, Xiao Qiong ^c   Tong, Xiao ^a   Shen, Xi Hui ^a   Yang, Rong Ge ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b HUZHOU UNIVERSITY   (China)

^c Shouguang Center for Diseases Control and Prevention   (China)

Author keywords

Drug Resistant mutation; Drug treated; Former blood donors; HIV 1

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; BIOSURVEILLANCE; BLOOD DONOR; CHINA; COMPUTER PROGRAM; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADULT; BLOOD DONORS; CHINA; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SENTINEL SURVEILLANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855231799     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-011-3210-0     Document Type: Article

References (15)

1. A. Antinori M. Zaccarelli A. Cingolani 2002 Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure AIDS Res Hum Retrov 18 835 838 10.1089/08892220260190308 1:CAS:528:DC%2BD38XmvVSktb8%3D (Pubitemid 35034664)
2. V. Calvez D. Costagliola D. Descamps 2002 Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial Antivir Ther 7 211 218 12487389 1:CAS:528: DC%2BD38XpsleltLo%3D (Pubitemid 36427147)
3. E. De Clercq 2009 Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int J Antimicrob Ag 33 307 320 10.1016/j.ijantimicag. 2008.10.010
4. T. Gingeras G. Mamtora N. Shen 1996 Genetic analysis of HIV-1 plasma using high density oligonucleotide arrays and dideoxynucleotide sequencing Antivral Therapy 1 Suppl.1 42
5. K. Hertogs M. P. de Bethune V. Miller 1998 A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs Antimicrob Agents Ch 42 269 276 10.1093/jac/42.2.269 1:CAS:528:DyaK1cXnsFGrug%3D%3D (Pubitemid 28114430)
6. A. J. Japour D. L. Mayers V. A. Johnson 1993 Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group Antimicrob Agents Ch 37 1095 1101 1:CAS:528:DyaK3sXksVSit70%3D (Pubitemid 23141326)
7. V. A. Johnson F. Brun-Vezinet B. Clotet 2008 Update of the drug resistance mutations in HIV-1: Spring 2008 Top HIV Med 16 62 68 18441382
8. R. Kantor R. Machekano M. J. Gonzales 2001 Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs Nucleic Acids Research 29 296 299 11125118 10.1093/nar/29.1.296 1:CAS:528:DC%2BD3MXjtlWmtLY%3D (Pubitemid 32054474)
9. D. Lecossier N. S. Shulman L. Morand-Joubert 2005 Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine J Acq Immune Defic Syndr 38 37 42 10.1097/00126334-200501010- 00007 1:CAS:528:DC%2BD2cXhtVylt7bL (Pubitemid 40094116)
10. P. Liu K. Xiang H. Tang 2008 Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China AIDS Res Hum Retrov 24 1 6 10.1089/aid.2007.0144
11. A. G. Marcelin P. Flandre J. Pavie 2005 Clinically relevant genotype interpretation of resistance to didanosine Antimicrob Agents Ch 49 1739 1744 10.1128/AAC.49.5.1739-1744.2005 1:CAS:528:DC%2BD2MXktFSntr8%3D (Pubitemid 40631583)
12. S. Y. Rhee M. J. Gonzales R. Kantor 2003 Human immunodeficiency virus reverse transcriptase and protease sequence database Nucleic Acids Research 31 298 303 12520007 10.1093/nar/gkg100 1:CAS:528:DC%2BD3sXhvFSmsLk%3D (Pubitemid 36150389)
13. R. W. Shafer M. A. Winters S. Palmer 1998 Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients Ann Intern Med 128 906 911 9634429 1:CAS:528:DyaK1cXjs1Ogsrw%3D (Pubitemid 28289485)
14. A. M. Wensing D. A. van de Vijver G. Angarano 2005 Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management J Infect Dis 192 958 966 16107947 10.1086/432916 (Pubitemid 41266791)
15. S. Yerly L. Kaiser E. Race 1999 Transmission of antiretroviral-drug- resistant HIV-1 variants Lancet 354 729 733 10475184 10.1016/S0140-6736(98) 12262-6 1:STN:280:DyaK1Mvgt1Wluw%3D%3D (Pubitemid 29407396)